Annovis Bio, Inc. (ANVS)
$
2.03
+0.22 (10.84%)
Key metrics
Financial statements
Free cash flow per share
-678.2502
Market cap
39.6 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
6.1068
Income quality
2.1166
Average inventory
0
ROE
-0.0066
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Annovis Bio, Inc., a clinical-stage drug platform company focused on developing treatments for neurodegeneration, has made significant strides with its lead compound, Buntanetap. This orally administered drug has successfully completed Phase 2a clinical trials targeting both Alzheimer's disease (AD) and Parkinson's disease. Additionally, Buntanetap is currently undergoing clinical trials for Alzheimer's disease specifically in Down Syndrome patients and other chronic neurodegenerative disorders. The company's commitment to addressing these complex conditions is further exemplified by its development of ANVS405, aimed at safeguarding against traumatic brain injury and stroke. Furthermore, ANVS301 is in Phase I clinical trials, with the goal of enhancing cognitive capabilities in later stages of AD and dementia. Amid its clinical advancements, the company earned an interest income of $331,849.00 showcasing its financial investments. It also reported depreciation and amortization expenses of $0.00 reflecting the wear and tear of its assets. The operational overhead is evident in the company’s selling, general, and administrative expenses totaling $6,699,000.00. In terms of financial obligations, the company incurred an interest expense of $1,853,189.00 illustrating its debt servicing responsibilities, alongside an income tax expense of $0.00 indicating its tax obligations. The stock for Annovis Bio, Inc. is currently affordable at $2.32 making it a suitable option for budget-conscious investors. However, it is worth noting that the stock has a low average trading volume of 568,896.00 which indicates lower market activity. With a market capitalization of $39,557,049.00 the company is classified as a small-cap player within the biotechnology landscape. It is a key player in the Biotechnology industry, significantly contributing to the overall market dynamics. Moreover, Annovis Bio, Inc. operates under the Healthcare sector, driving innovation and growth while seeking to impact the treatment of neurodegenerative diseases positively.
Is Annovis Bio, Inc. (ANVS) a good investment?
Investing in Annovis Bio, Inc. (ANVS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Annovis Bio, Inc. (ANVS)'s stock forecast?
Analysts predict Annovis Bio, Inc. stock to fluctuate between $1.11 (low) and $10.54 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Annovis Bio, Inc.'s market capitalization?
As of 2025-10-16, Annovis Bio, Inc.'s market cap is $39,557,049, based on 19,486,231 outstanding shares.
How does Annovis Bio, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Annovis Bio, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Annovis Bio, Inc. (ANVS) stock?
To buy Annovis Bio, Inc. (ANVS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANVS. Place an order (Market, Limit, etc.).
What is the best time to invest in Annovis Bio, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Annovis Bio, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2,018.50 | Growth: 32,299.68%.
Where can I find Annovis Bio, Inc.'s investor relations reports?
Visit https://www.annovisbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Annovis Bio, Inc.?
You can explore historical data from here
What is the all-time high and low for Annovis Bio, Inc. stock?
All-time high: $43.37 (2021-08-12) | All-time low: $1.11 (2025-04-09).
What are the key trends affecting Annovis Bio, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof).
globenewswire.com
MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof) in a registered direct offering. The closing of the offering is expected to occur on or about October 13, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap's ability to attenuate inflammation and improve cellular health in Alzheimer's patients, suggesting potential disease-modifying effects beyond symptomatic relief.
globenewswire.com
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development.
globenewswire.com
MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of a new article in a peer-reviewed journal Biomolecules , which describes the pharmacokinetic (PK) profile of a new crystal form of buntanetap and compares it to the old form across several studies including mice, dogs, and humans.
globenewswire.com
MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it received notification (the "Acceptance Letter") from the New York Stock Exchange ("NYSE") that the NYSE has accepted the Company's previously-submitted plan (the "Plan") to regain compliance with the NYSE's continued listing standards relating to minimum market capitalization and stockholders' equity.
zacks.com
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com
Malvern, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and first quarter 2025 financial results.
globenewswire.com
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders' equity was less than $50 million.
globenewswire.com
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results.
See all news
